Bourne Lent Asset Management’s Pfizer PFE Stock Holding History

Bourne Lent Asset Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Hold	37,275	–	–	0.38%	33
2025 Q4	$928K	Buy	37,275 +100	+0.3%	+$2.52K	0.31%	31
2025 Q3	$947K	Sell	37,175 -1,080	-3%	-$26.7K	0.34%	32
2025 Q2	$927K	Buy	38,255 +18,200	+91%	+$424K	0.36%	33
2025 Q1	$508K	Sell	20,055 -850	-4%	-$22.2K	0.22%	37
2024 Q4	$555K	Hold	20,905	–	–	0.21%	36
2024 Q3	$605K	Hold	20,905	–	–	0.23%	37
2024 Q2	$585K	Sell	20,905 -900	-4%	-$24.8K	0.22%	37
2024 Q1	$605K	Sell	21,805 -4,000	-16%	-$111K	0.24%	37
2023 Q4	$743K	Sell	25,805 -11,000	-30%	-$333K	0.3%	32
2023 Q3	$1.22M	Hold	36,805	–	–	0.54%	28
2023 Q2	$1.35M	Hold	36,805	–	–	0.47%	28
2023 Q1	$1.5M	Hold	36,805	–	–	0.57%	26
2022 Q4	$1.89M	Sell	36,805 -1,174	-3%	-$56.3K	0.81%	22
2022 Q3	$1.66M	Hold	37,979	–	–	0.72%	24
2022 Q2	$1.99M	Sell	37,979 -700	-2%	-$35.7K	0.79%	25
2022 Q1	$2M	Hold	38,679	–	–	0.63%	26
2021 Q4	$2.28M	Hold	38,679	–	–	0.61%	23
2021 Q3	$1.66M	Hold	38,679	–	–	0.48%	29
2021 Q2	$1.51M	Hold	38,679	–	–	0.43%	30
2021 Q1	$1.4M	Buy	38,679 +700	+2%	+$24.9K	0.45%	30
2020 Q4	$1.4M	Buy	37,979 +9,543	+34%	+$350K	0.46%	28
2020 Q3	$990K	Hold	28,436	–	–	0.38%	27
2020 Q2	$882K	Hold	28,436	–	–	0.38%	28
2020 Q1	$881K	Sell	28,436 -1,054	-4%	-$35.9K	0.47%	26
2019 Q4	$1.1M	Sell	29,490 -3,352	-10%	-$119K	0.52%	25
2019 Q3	$1.12M	Sell	32,842 -527	-2%	-$19.2K	0.54%	23
2019 Q2	$1.37M	Hold	33,369	–	–	0.66%	23
2019 Q1	$1.34M	Hold	33,369	–	–	0.67%	23
2018 Q4	$1.38M	Sell	33,369 -2,013	-6%	-$83.6K	0.82%	23
2018 Q3	$1.48M	Hold	35,382	–	–	0.71%	23
2018 Q2	$1.22M	Buy	35,382 +190	+0.5%	+$6.49K	0.64%	23
2018 Q1	$1.19M	Sell	35,192 -1,912	-5%	-$65.7K	0.64%	23
2017 Q4	$1.27M	Hold	37,104	–	–	0.69%	23
2017 Q3	$1.26M	Hold	37,104	–	–	0.65%	23
2017 Q2	$1.18M	Sell	37,104 -4,534	-11%	-$143K	0.65%	23
2017 Q1	$1.35M	Hold	41,638	–	–	0.74%	23
2016 Q4	$1.28M	Buy	41,638 +10,059	+32%	+$307K	0.77%	24
2016 Q3	$1.01M	Buy	31,579 +527	+2%	+$17.6K	0.75%	23
2016 Q2	$1.04M	Buy	31,052 +816	+3%	+$26K	0.81%	24
2016 Q1	$850K	Hold	30,236	–	–	0.68%	24
2015 Q4	$926K	Hold	30,236	–	–	0.7%	22
2015 Q3	$901K	Hold	30,236	–	–	0.74%	21
2015 Q2	$962K	Sell	30,236 -6,377	-17%	-$208K	0.76%	19
2015 Q1	$1.21M	Buy	+36,613	New	+$1.16M	0.92%	18

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Bourne Lent Asset Management's PFE Position: Q1 2026 in Review

Bourne Lent Asset Management held its Pfizer (PFE) position steady in Q1 2026 at 37,275 shares worth $1.05M. The position accounts for 0.38% of the portfolio, ranked #33.

Bourne Lent Asset Management first reported a position in PFE in Q1 2015 and has held it in 45 quarters since. The position peaked at $2.28M in Q4 2021. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Bourne Lent Asset Management held 37,275 shares of Pfizer worth $1.05M as of Q1 2026.
Bourne Lent Asset Management left its Pfizer share count unchanged in Q1 2026.
Pfizer made up 0.38% of Bourne Lent Asset Management's portfolio in Q1 2026, its #33 holding.
Bourne Lent Asset Management first reported a position in Pfizer in Q1 2015 and has held it in 45 quarters since.
Bourne Lent Asset Management's Pfizer position peaked at $2.28M in Q4 2021.
2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Bourne Lent Asset Management's 13F filing for Q1 2026, filed 17 Apr 2026.